BioCentury | Dec 21, 2017
Translation in Brief

Replacing the replacements

...Jan. 7. 2016)). Duke University licensed Opara’s porcine β cell encapsulation technology in 1998 to MicroIslet Inc....
...constructs in rats corrects abnormalities of ovarian failure.” Nature Communications (2017) Allison Johnson, Staff Writer Islet Sciences Inc. MicroIslet Inc. Semma...
BioCentury | May 25, 2009
Finance

Stem cell stocks

...Stem cell stocks Company 5/22 cls 5/22 % chg Week % chg MicroIslet Inc. (OTCBB:MIIS) $0.01 67%...
BioCentury | May 21, 2009
Distillery Techniques

Technology: Drug platforms

...Ongoing studies in monkeys are determining the minimum immunosuppressive therapy required for successful transplantation. MicroIslet Inc.'s MicroIslet-P...
BioCentury | Nov 6, 2008
Targets & Mechanisms

A tolerant alternative to immunosuppression

...graft acceptance and induction of immune tolerance." Nevertheless, Ingrid Stuiver, senior director of research at MicroIslet Inc....
...assure reproducibility." The company is planning its IND submission to enter the clinic with its MicroIslet...
...Md. Harvard Medical School , Boston, Mass. Living Cell Technologies Ltd. (ASX:LCT; Pink:LVCLY), Hawthorn, Australia MicroIslet Inc....
BioCentury | Aug 25, 2008
Company News

MicroIslet management update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Hired: Brian Conn as VP of corporate finance and CFO, formerly director of finance at Millipore Corp. WIR Staff...
BioCentury | Jul 7, 2008
Clinical News

MicroIslet-P: Phase I start

...submit an IND to begin a Phase I trial. MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Product: MicroIslet-P...
BioCentury | Mar 10, 2008
Company News

MicroIslet scientific advisory board update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Appointed: John Buse, president for medicine and science at the American Diabetes Association; David Scharp, EVP and CMO of Novacell Inc.; Miguel Carlos Riella, chief...
BioCentury | Mar 6, 2008
Distillery Therapeutics

This Week in Therapeutics

...polyethylene glycol-encapsulated human pancreatic islet cells in Phase I/II testing for type 1 diabetes. MicroIslet Inc.'s MicroIslet-P...
BioCentury | Feb 4, 2008
Company News

MicroIslet management update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Departed: Jonathan Lakey as president and CSO while remaining a director WIR Staff...
BioCentury | Feb 4, 2008
Company News

MicroIslet scientific advisory board update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Appointed: Ron Goldblum, formerly VP of clinical development at Elan Corp. plc ; and Chris Marsh, co-director of the center for organ and cell transplantation...
Items per page:
1 - 10 of 38
BioCentury | Dec 21, 2017
Translation in Brief

Replacing the replacements

...Jan. 7. 2016)). Duke University licensed Opara’s porcine β cell encapsulation technology in 1998 to MicroIslet Inc....
...constructs in rats corrects abnormalities of ovarian failure.” Nature Communications (2017) Allison Johnson, Staff Writer Islet Sciences Inc. MicroIslet Inc. Semma...
BioCentury | May 25, 2009
Finance

Stem cell stocks

...Stem cell stocks Company 5/22 cls 5/22 % chg Week % chg MicroIslet Inc. (OTCBB:MIIS) $0.01 67%...
BioCentury | May 21, 2009
Distillery Techniques

Technology: Drug platforms

...Ongoing studies in monkeys are determining the minimum immunosuppressive therapy required for successful transplantation. MicroIslet Inc.'s MicroIslet-P...
BioCentury | Nov 6, 2008
Targets & Mechanisms

A tolerant alternative to immunosuppression

...graft acceptance and induction of immune tolerance." Nevertheless, Ingrid Stuiver, senior director of research at MicroIslet Inc....
...assure reproducibility." The company is planning its IND submission to enter the clinic with its MicroIslet...
...Md. Harvard Medical School , Boston, Mass. Living Cell Technologies Ltd. (ASX:LCT; Pink:LVCLY), Hawthorn, Australia MicroIslet Inc....
BioCentury | Aug 25, 2008
Company News

MicroIslet management update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Hired: Brian Conn as VP of corporate finance and CFO, formerly director of finance at Millipore Corp. WIR Staff...
BioCentury | Jul 7, 2008
Clinical News

MicroIslet-P: Phase I start

...submit an IND to begin a Phase I trial. MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Product: MicroIslet-P...
BioCentury | Mar 10, 2008
Company News

MicroIslet scientific advisory board update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Appointed: John Buse, president for medicine and science at the American Diabetes Association; David Scharp, EVP and CMO of Novacell Inc.; Miguel Carlos Riella, chief...
BioCentury | Mar 6, 2008
Distillery Therapeutics

This Week in Therapeutics

...polyethylene glycol-encapsulated human pancreatic islet cells in Phase I/II testing for type 1 diabetes. MicroIslet Inc.'s MicroIslet-P...
BioCentury | Feb 4, 2008
Company News

MicroIslet management update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Departed: Jonathan Lakey as president and CSO while remaining a director WIR Staff...
BioCentury | Feb 4, 2008
Company News

MicroIslet scientific advisory board update

MicroIslet Inc. (OTCBB:MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Appointed: Ron Goldblum, formerly VP of clinical development at Elan Corp. plc ; and Chris Marsh, co-director of the center for organ and cell transplantation...
Items per page:
1 - 10 of 38